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ABSTRACT
Background

Recent research suggests that mental health problems in spouses of cancer survivors are associated with worse
mental health in the survivors themselves. Adequately treating spousal mental health problems therefore
represents an opportunity to improve outcomes for both cancer survivors and their co-surviving family
members.

Objective

Using nationally representative data, this study sought to determine how depression treatment differs between
spouses of cancer survivors with depression compared to the general married population and assess rural/urban
disparities in treatment.

Design

The design of the study is cross sectional.

Participants

Data are from the Medical Expenditures Panel Survey, a household-based survey of US adults; we concatenated
data from 2004 to 2013. We identified spouses of cancer survivors (n = 225) and a comparison group of married
adults (n = 3678).

Main Measures
Key measures included depression, guideline concordance of depression treatment (at least four prescriptions
related to depression treatment, or at least eight psychotherapy or counseling visits), and sociodemographic
characteristics. Logistic regressions evaluated the association between whether their spouse had cancer and
receipt of guideline-concordant treatment, controlling for sociodemographic characteristics; secondary analyses
included rurality as a moderator. Analyses were weighted to account for the complex sampling design.

Key Results
Spouses of cancer survivors were 33% less likely to receive guideline-concordant depression treatment than
comparison spouses (odds ratio (OR) 0.67, 95% confidence interval (CI) 0.45–0.99), controlling for covariates.
Rural-urban disparities were observed: rural spouses of cancer survivors were 72% less likely to receive
guideline-concordant treatment (OR 0.28, 95% CI 0.11–0.68) than rural comparison spouses. Spouses of cancer
survivors and comparison spouses were no different in their receipt of any treatment versus no treatment.

Conclusions
Spouses of cancer survivors with depression may be at increased risk of non-guideline-concordant depression
treatment, particularly in rural areas. The findings have implications for identifying and educating individuals
with depression in primary care and other clinical areas.
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INTRODUCTION
There are an estimated 15.5 million cancer survivors in the USA1 (defined as any person diagnosed with cancer,
from the time of initial diagnosis2). Given that the adverse impacts of cancer extend beyond the cancer patient
themselves,2, 3 millions more family members are considered “co-survivors” of the disease. Co-survivors often
serve as informal cancer caregivers, playing a critical role in the well-being of individuals with cancer. In addition
to supporting the survivor through their illness, co-survivors often struggle with their own emotional distress.
The caregivers of cancer survivors have been found to have equal, if not greater, rates of depression than the
survivors themselves (12–59%).4 Spouses in particular often experience greater burden, strain, or distress than
other family caregivers5, 6 and are more likely than the general population to experience depression.7, 8
Recent research has shown that when their spouses experienced depressed mood, cancer survivors were four
times more likely to become depressed over the next year,9, 10 supporting theoretical and emerging empirical
work around the interrelationship between families/caregivers and cancer survivors.11 Given the association
between depression in cancer survivors and adverse outcomes ranging from decreased medication adherence
to premature mortality,12–17 appropriately treating spousal depression may afford an opportunity to improve
outcomes for both cancer survivors and their spouses. However, despite the existence of effective
pharmacotherapy and psychotherapy treatments,18many cancer caregivers (including spouses) may be at risk
for under-treatment of depression,19 as informal caregivers often report struggling with self-care,20 and likely
face time, cost, and access constraints that may be barriers to receiving health care. Furthermore, low
socioeconomic status has been associated with less adequate depression treatment21 and rural populations
face known mental health treatment challenges.22 Yet, we know very little about the unique needs and
outcomes of rural caregivers.
This study sought to evaluate how cancer caregivers with depression currently receive treatment in the USA.
Specifically, we sought to determine how treatment patterns for spouses of cancer survivors differ from the
general population, and whether there are socioeconomic or geographic disparities in treatment rates. Better
understanding treatment patterns and disparities among cancer caregivers will inform medical practice and
caregiver education, with important implications for the well-being of cancer survivors and their families.

METHODS
Data were obtained from the Medical Expenditures Panel Survey (MEPS). The MEPS is a household-based,
nationally representative survey of US adults. Each year, the MEPS collects data on a new panel of households
and each panel is followed for five time points over a 2.5-year period. For this study, we concatenated data from
panels 9–17 collected between 2004 and 2013. Detailed information about MEPS methodology and data is
available at http://meps.ahrq.gov.

Sample Selection

MEPS respondents were eligible for this study if they (1) were married to someone with or without cancer and
(2) reported having depression. To identify depressed spouses of cancer survivors, we first used the MEPS
medical conditions file to identify adults who had a cancer-related health-problem, medical event, or disability.
Adults with any type of cancer or malignancy (excluding those with only non-melanoma skin cancer) were
categorized as survivors. All other adults were categorized as general population.
We then linked both survivors and the general population with their spouses (if applicable) using a spousal ID.
Depression status was then determined using the Conditions Enumerations section of the MEPS, in which
participants reported their physical and mental/emotional conditions, as well as conditions related to any
medical events or disabilities. Using this information, MEPS coders assign truncated ICD-9 codes. Participants
with ICD-9 code 296 or 311, during any round, were classified as having depression. All depressed spouses of

cancer survivors were included in the final sample; couples in which both spouses had cancer were excluded. In
the comparison sample of depressed spouses in the general population, when couples both reported depression
an index spouse was randomly selected. This resulted in an eligible sample of 4001 adults (n = 229 spouses of
cancer survivors, n = 3772 comparison spouses; Fig. 1).

Figure 1. Identification of eligible participants. MEPS Medical Expenditures Panel Survey. Data are from 2004
to 2013.

Key Measures
Dependent Variable: Depression Treatment

Based on guidelines from the 2010 American Psychological Association23and the definitions used in previous
research,21, 24–26 guideline-concordant treatment of depression was defined as receiving at least four
prescriptions related to depression treatment or at least eight outpatient or office-based psychotherapy or
counseling visits. Using the MEPS prescription file, we identified whether a respondent received prescriptions
indicated for the treatment of depression as defined by Multum Lexicon Drug Database (subclassification code
249).27 MEPS respondents reported the name of any prescribed medicine they purchased or otherwise
obtained during each round. Each original purchase and any subsequent refills were recoded as distinct
medications. Using the MEPS Outpatient Department Visits and MEPS Office-Based Medical Provider Visits files,
we identified the number of visits involving psychotherapy. Prescriptions and psychotherapy visits were counted

over a rolling three-round period (i.e., time points 1–3, time points 2–4, and/or time points 3–5); four
prescriptions or eight psychotherapy visits in any period were counted as receiving guideline-concordant
treatment. Prescriptions were assumed to be for a minimum of 30 days, and psychotherapy for a minimum of
30 min. We also categorized respondents who had received any treatment versus no treatment for depression.

Independent Variable: Co-Survivor/Comparison Status

Co-survivors (here referring specifically to spouses of cancer survivors) and comparisons (spouses in the general
population) with depression were identified as described above.

Covariates

Following Keller et al.,26 predisposing, enabling, and need factors were considered as covariates.28 Predisposing
factors included age, gender, race/ethnicity (white non-Hispanic versus other), education (high school or less
versus some college or more), employment status (employed versus not employed), percent of the federal
poverty level (100, 200, 300, or 400%+), rurality (Metropolitan Statistical Area, rural versus urban), and region of
residence (Northeast, Midwest, South, or West). Enabling factors included health insurance coverage (any
public, private only, or uninsured) and having a usual source of care (yes versus no). Need factors included
number of health conditions, self-reported health (good/fair/poor versus excellent/very good), health service
use in the past 12 months (low < 4 visits versus high 4+ visits), and level of depressed mood (Patient Health
Questionnaire-2 29). Covariates were measured at baseline (round 1); if baseline data were missing, the variable
was back-filled with data from the next available time point. For co-survivors, we also assessed the survivor’s
cancer type (blood, breast, colorectal, prostate, other, or multiple) and time since diagnosis (<5 years, 5+ years,
or unknown/unreported) as reported in the medical conditions file; these data were for descriptive purposes
only.

Analytic Approach

Descriptive statistics (cross-tabulations; means and standard deviations) were calculated on all covariates. Cosurvivors and comparison spouses were compared on all covariates using chi-squared and t tests. Among cosurvivors and comparison spouses with depression, we calculated the proportion receiving guideline-concordant
treatment, and any treatment. We then ran a bivariate logistic regression, regressing receipt of guidelineconcordant treatment on co-survivor/comparison status. The predisposing, enabling, and need covariates and
panel number were then added to this model in a multivariable logistic regression. Finally, moderation was
assessed by including interaction terms for (1) rurality*co-survivor status and (2) poverty*co-survivor status in
separate regressions. All analyses were conducted in SAS (v. 9.4) using survey weighting procedures to adjust for
the complex sampling frame of the MEPS.

Approach to Missing Data

This study was conducted as a complete case analysis, and those with missing covariate data were dropped from
the analysis (n = 4 spouses of cancer survivors (1.8%) and n = 94 comparison spouses (2.5%)). Those dropped due
to missing data were slightly older (53 versus 49, p < 0.01), more likely to be from the western USA (38 versus
25%, p = 0.04), less likely to have a usual source of care (78 versus 87%, p < 0.01), and had fewer health
conditions (7 versus 9, p < 0.01). They were also less likely to receive guideline-concordant depression treatment
(50 versus 62%, p = 0.01). They did not differ significantly on other covariates.

Sensitivity Analysis

To assess whether our findings are robust to our operationalization of guideline concordance, we conducted
sensitivity analyses testing six psychotherapy visits (the number often approved by insurance companies) rather
than eight.

RESULTS
Table 1 depicts the characteristics of the samples. Co-survivors were older than comparison spouses (mean ages
61 versus 50 years, p < 0.0001). Almost two thirds (66%) of the comparisons were female, while 58% of the cosurvivors were female (p = 0.07). Comparisons were also more likely to be employed (56 versus 39%, p < 0.01).
Most participants in both groups were white non-Hispanic and reported at least some college education.
Approximately 30% of participants reported incomes at or below 200% of the federal poverty level, and
approximately 80% lived in an urban area. Co-survivors were more likely to have only private insurance (21
versus 14%), while comparisons were more likely to be uninsured (8 versus 3%, p < 0.0001). Nearly all
participants (~90%) reported having a usual source of care. Co-survivors reported more health conditions than
comparisons (mean conditions: 12 versus 9, p < 0.0001). Co-survivors were also more likely to report poor selfrated health (69 versus 59%, p = 0.0059) and high service use in the past 12 months (62 versus 50%, p = 0.0037).
Table 1 Survey Weighted Characteristics of Adults With Depression, Medical Expenditures Panel Survey (2004–
2013)
Weighted number
Unweighted number
Sociodemographics
Age (years; mean, SD)
Gender
Male
Female
Race/ethnicity
Other
White (non-Hispanic)
Education
High school or less
Some college or more
Employment status
Not employed
Employed
Percent of federal poverty level
100
200
300
400+
MSA
Rural
Urban
Region
Northeast
Midwest
South
West
Insurance coverage

Co-survivors
582,548
225
Mean (SD) or %

Comparisons
9,165,501
3,678
Mean (SD) or
%

P value

60.93 (0.98)

49.44 (0.27)

42.34
57.66

34.12
65.88

< 0.0001
0.0671

34.71
65.29

36.95
63.05

48.25
51.75

44.08
55.92

60.68
39.32

44.38
55.62

5.67
26.71
25.51
42.11

6.43
23.07
28.19
42.32

18.22
81.78

18.93
81.07

22.80
23.30
33.49
20.41

15.28
25.26
37.18
22.29

0.5420
0.3001
< 0.0001
0.7076

0.8267
0.4201

< 0.0001

Any public
Private only
Uninsured
Usual source of care
No
Yes
Health conditions (mean, SD)
Self-reported health
Good/fair/poor
Excellent/very good
Service use (past 12 months)
Low (< 4 visits)
High (4+ visits)
Cancer characteristics
Cancer type
Blood
Breast
Colorectal
Prostate
Multiple
Other
Time since diagnosis
< 5 years
5+ years
Unknown/unreported
Treatment status
Not receiving treatment during
survey period
Received treatment during survey
period
SD standard deviation

75.33
21.21
3.45

77.17
14.48
8.35

7.88
92.12
11.62 (0.59)

11.10
88.90
9.26 (0.13)

68.99
31.01

59.08
40.92

37.67
62.33

49.92
50.08

8.43
20.20
5.01
17.69
7.15
41.51
45.71
29.47
24.82
64.53

0.1898
< 0.0001
0.0059
0.0037

NA

NA

NA

NA

NA

NA

35.47

In the unadjusted data, two thirds of both co-survivors with depression and comparisons reported receiving
guideline-concordant treatment (data not tabled). Table 2 shows the results of the weighted multivariable
logistic regression of the association between co-survivor status (i.e., spouses of cancer survivors with
depression versus comparison spouses with depression) and receipt of guideline-concordant depression
treatment. After controlling for covariates, co-survivors were 33% less likely to receive guideline-concordant
depression treatment (odds ratio [OR] = 0.67, 95% confidence interval [CI] = 0.45–0.99). Predisposing, enabling,
and need factors were also associated with receipt of guideline-concordant treatment (Table 2; written
summary available in Online Appendix).
Table 2 Association Between Spousal Caregiving Status and Guideline Concordant Depression Treatment
(Medical Expenditures Panel Survey, 2004–2013)

Co-survivor/comparison status
Spouse of cancer survivor

Bivariate
Multivariable
OR
95% CI
OR
95% CI
Lower Upper
Lower Upper
1.02

0.70

1.49

0.67

0.45

0.99

Comparison spouse (ref)
Covariates
Age (years)
1.01
1.01
Gender
Male (ref)
Female
1.24
1.04
Race/ethnicity
Other
0.47
0.37
White (non-Hispanic) (ref)
Education
High school or less
0.79
0.66
Some college or more (ref)
Employment status
Not employed for pay
0.78
0.64
Employed (ref)
Percent of federal poverty level
100
0.82
0.58
200
0.72
0.56
300
0.82
0.66
400+ (ref)
MSA
Rural
1.17
0.88
Urban (ref)
Region
Midwest
1.32
1.03
Northeast
1.10
0.83
South
1.14
0.90
West (ref)
Insurance coverage
Any public
1.50
1.14
Private only
1.48
1.06
Uninsured (ref)
Usual source of care
No
0.56
0.43
Yes (ref)
Health conditions (number)
1.08
1.05
Self-reported health
Good/fair/poor (ref)
Excellent/very good
0.82
0.67
Service use (past 12 months)
Low (< 4 visits) (ref)
High (4+ visits)
1.33
1.12
Depressed mooda
1.03
0.98
Note: Survey-weighted models; multivariable model also controls for panel number
OR odds ratio, CI confidence interval
a
Measured by the Patient Health Questionnaire 2 (one-point increase)

1.02
1.47
0.60
0.94
0.96
1.16
0.93
1.02
1.55
1.69
1.47
1.44
1.97
2.05
0.72
1.10
0.99
1.58
1.09

There was a significant interaction between rurality and co-survivor status (pinteraction = 0.02). Rural co-survivors
were 72% less likely to receive guideline-concordant depression treatment (OR 0.28, 95% CI 0.11–0.68) than
rural comparisons. Figure 2 shows the predicted probabilities of receipt of guideline-concordant treatment,
controlling for covariates (with age centered at 50): 40% of rural co-survivors with depression received
guideline-concordant treatment, versus 71% of rural comparison spouses, 66% of urban comparison spouses,
and 61% of urban co-survivors.

Figure 2 Predicted probabilities of guideline-concordant treatment among spouses of cancer survivors (“cosurvivors,” blue bars) and comparison spouses in the general population (orange bars), by urbanicity. a
Significant difference from rural and urban comparisons (p < 0.05); borderline difference from urban cosurvivors (p < 0.10). b Significant difference from rural co-survivors (p < 0.05); borderline difference from
urban co-survivors (p < 0.10)
Poverty level did not moderate the association between co-survivor/comparison status and guidelineconcordant treatment (pinteraction = 0.36; data not tabled). There was no association between co-survivor status
and receipt of any depression treatment versus no treatment (Table 3). In sensitivity analyses, changing the
definition of guideline concordance from eight psychotherapy visits to six visits did not change the results.
Table 3 Association Between Spousal Caregiving Status and Receipt of Any Depression Treatment (Medical
Expenditures Panel Survey, 2004–2013)
Bivariate
OR
Co-survivor/comparison status
Spouse of cancer survivor
Comparison spouse (ref)
Covariates
Age (years)
Gender
Male (ref)
Female
Race/ethnicity
Other
White (non-Hispanic) (ref)
Education
High school or less
Some college or more (ref)
Employment status

1.16

95% CI
Lower

Upper

0.76

1.77

Multivariable
OR

95% CI
Lower

Upper

0.81

0.53

1.25

1.01

1.00

1.02

1.43

1.16

1.75

0.43

0.33

0.55

0.82

0.66

1.03

Not employed for pay
0.75
Employed (ref)
Percent of federal poverty level
100
0.86
200
0.70
300
0.90
400+ (ref)
MSA
Rural
1.21
Urban (ref)
Region
Midwest
1.10
Northeast
1.04
South
1.21
West (ref)
Insurance coverage
Any public
1.49
Private only
1.39
Uninsured (ref)
Usual source of care
No
0.56
Yes (ref)
Health conditions (number)
1.10
Self-reported health
Good/fair/poor (ref)
Excellent/very good
0.84
Service use (past 12 months)
Low (< 4 visits) (ref)
High (4+ visits)
1.45
a
Depressed mood
1.01
Note: Survey-weighted models; multivariable model also controls for panel number
OR odds ratio, CI confidence interval
a
Measured by the Patient Health Questionnaire 2 (one-point increase)

0.60

0.94

0.59
0.53
0.71

1.27
0.92
1.14

0.92

1.60

0.84
0.76
0.95

1.44
1.44
1.53

1.11
0.98

1.99
1.99

0.43

0.73

1.07

1.13

0.67

1.05

1.18
0.95

1.78
1.08

DISCUSSION

Co-survivors serve as an integral part of the care team for cancer patients, but may also suffer from unaddressed
emotional needs. We performed an analysis of an existing database and found that spouses of cancer survivors
were less likely to receive guideline-concordant depression treatment than comparison spouses. Our findings
support previous research indicating that distressed family caregivers of lung cancer patients underuse mental
health services.30 In our analysis, co-survivors in rural areas were particularly at risk. We did not observe similar
disparities in socioeconomic status, and co-survivors and comparisons with depression did not differ in their
receipt of any depression treatment (versus no depression treatment). To our knowledge, this is the first study
to evaluate rates of guideline-concordant depression care among caregivers.
It is noteworthy that we found differences in guideline-concordant treatment, even though all eligible subjects
reported having depression. One interpretation of this finding is that co-survivors, and particularly rural cosurvivors, are at risk for under-treatment of depression. Under-treatment of depression is prevalent among the
general population.31Caregivers may be disproportionately affected as they often struggle with self-

care20 which may extend into mental health care.30 Cancer caregivers have reported seeing mental health
service use as a “last resort” and prioritizing the care recipient’s needs above their own,32 potentially leading
them to be less likely to seek out or adhere to treatment for their depression.
In addition, expectations and assumptions around cancer and depression may play a role. Anecdotal evidence
from our clinical practice suggests that many co-survivors and patients interpret their depression as part of the
“cancer experience”: they feel that they are supposed to be depressed and assume that it is part of the
“necessary suffering” of cancer, and therefore do not seek treatment. They may feel that since they cannot
change the circumstances or their survivor’s diagnosis, they also cannot change or control their depression.
However, to our knowledge, this mindset has not been examined in the literature. Qualitative and quantitative
studies are needed to determine to what extent this mindset may act as a modifiable barrier to depression care.
An alternative explanation of these findings relates to differing levels of depression symptoms and/or treatment
needs in co-survivors compared to the general population. Although treatment guidelines are a useful tool, they
are not meant to supersede clinical judgment. It is therefore possible that lower (guideline non-concordant)
levels of treatment were the best course of care for some co-survivors in this study. Although we controlled for
level of depressive symptoms to try to mitigate this confounding factor, studies with richer clinical data will be
needed to thoroughly evaluate this possibility.
Rural co-survivors received guideline-concordant treatment at particularly low levels. Previous work in the
general population33 found no overall rural-urban differences in receipt of depression treatment; similarly, in
our study, rural comparisons were statistically no different than urban comparisons to receive treatment. This
suggests that caregiving may contribute to under-treatment of depression in rural areas in unique ways.
Caregiving may amplify barriers to care observed in rural areas, including the well-documented shortage of
mental health providers34, 35 and possible greater perceptions of stigma and lower belief in the efficacy of and
need for treatment in samples from rural versus urban areas.36Caregiving in particular is associated with time
and cost burdens; in rural areas, where the geographical distance to a pharmacy or mental health provider may
be farther, such time costs may be more likely to present insurmountable barriers to care.
The findings from this study suggest opportunities for improving treatment of depression in cancer co-survivors,
ranging from co-survivor education to implications for clinical care. Caregiver-specific interventions, while
effective at decreasing burden, have not been successful in reducing caregivers’ depression.37 This emphasizes
the need for guideline-concordant depression treatment for caregivers who are experiencing depression. Given
the key role primary care plays in delivering mental health care,38, 39 this information may be particularly useful
for primary care practice. For example, asking about caregiving responsibilities may enable primary care
providers to identify high-risk patients who will benefit from close follow-up to maximize the probability that
they persist with their depression treatment. Enhancing mental health referrals with active follow-up may also
encourage uptake of recommended treatments, and may be particularly important in a rural population.
Oncology and specialty teams may also have a role in supporting co-survivors’ mental health, by integrating cosurvivors into family-centered cancer care. Several models for such integration are beginning to emerge,
including multidisciplinary hospital-based caregiver clinics,40 caregiver supports through palliative and hospice
care,41 and the Family Caregiver Program at the Department of Veterans Affairs.42 Most organizations,
however, do not yet have a formal, standardized mechanism for integrating co-survivors into cancer
care.43 Early involvement of palliative care—with an additional emphasis on evaluating caregiver depression
and stress—may also facilitate optimal mental health care for co-survivors.
Finally, enhanced patient education may improve depression treatment outcomes for co-survivors. Addressing
misconceptions about the efficacy and purpose of depression treatment—in general and for caregivers

specifically—may reduce feelings of futility and improve depression treatment plan adherence. Such education
may be particularly critical for rural co-survivors, for whom stigma and negative beliefs about depression and
treatment may be particularly relevant.36 Furthermore, community-level approaches to decreasing cultural
barriers such as stigma, or increasing access to mental health care may benefit all communities, and rural
communities in particular.
This study should be interpreted in light of several limitations. Our definition of guideline-concordant depression
treatment was guided by several assumptions and estimates made necessary by the dataset. Most panels of the
MEPS do not include questions about caregiving; actual caregiving involvement (i.e., spouses’ provision of
emotional, function, or financial support) is therefore assumed rather than documented. We could not assess
subjects’ adherence to treatment or determine the appropriateness of guideline non-concordant treatment on
an individual level. This study combined data across cancer types and we were unable to isolate cancer stage;
carcinomas in situ were therefore included along with later stage cancers. There are some differences between
the characteristics of the co-survivor and comparison groups. We opted to control for these possible
confounders in the statistical analysis rather than through matching procedures. Finally, we were only able to
examine spouses in this dataset; the findings may therefore not be generalizable to other caregiving populations
or relationships. Nevertheless, this study makes use of a large, national dataset with household-level data, and
provides compelling, generalizable evidence of differences in treatment for co-surviving spouses with
depression, particularly in rural areas. The findings should therefore spur future research to determine these
differences and the long-term impacts of such disparities with more precision.
In conclusion, this study found that spouses of cancer survivors were less likely to receive guideline-concordant
treatment for depression than the general population of married adults. Those in rural areas were at particularly
high risk of potential under-treatment. The findings highlight the need for enhanced follow-up among cancer cosurvivors, to encourage uptake of and adherence to depression treatment. Innovative approaches to addressing
barriers to mental health care, including family-centered cancer care and community-level approaches to
depression education and stigma reduction, may also improve co-survivor outcomes, particularly in rural areas.
Future research should examine and seek to mitigate clinical-, community-, and individual-level barriers to
depression care for cancer co-survivors, with a focus on how the barriers and solutions may differ by rurality.
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Appendix 1: Summary of the associations between study covariates
(predisposing, need, and enabling factors) and receipt of guideline
concordant treatment among spouses of cancer survivors.
Among the predisposing, need, and enabling factors, there were several correlates of guideline
concordant treatment (Table 2), controlling for co-survivor status. Among predisposing factors, older age (OR:
1.01, 95% CI: 1.01-1.02), female gender (OR:1.24, 95% CI: 1.04-1.47), and living in the Midwest (OR:1.32, 95% CI:
1.03-1.69) were associated with an increased likelihood of receiving guideline-concordant care, while non-white
race (OR: 0.47, 95% CI: 0.37-0.60), lower levels of education (OR: 0.79, 95% CI: 0.66-0.94), not working for pay
(OR: 0.78, 95% CI: 0.64-0.96), lower income (OR:0.72, 95% CI: 0.56-0.93, 200% FPL versus 400%) were associated
with a decreased likelihood of receiving guideline concordant depression treatment. Among enabling factors
insurance coverage was associated with an increased likelihood of receiving guideline concordant treatment
(any public insurance, OR: 1.50, 95% CI: 1.14- 1.97; private only, OR: 1.48, 95% CI: 1.06-2.05) and not having a
usual source of care was associated with a deceased likelihood of receiving guideline concordant treatment (OR:
0.56, 95% CI: 0.43-0.72). Finally, need factors were associated with receipt of guideline concordant depression
treatment: those with more health conditions and high service use were more likely to receive guideline
concordant treatment, and those with excellent or very good health were less likely to receive guideline
concordant treatment (OR: 1.08, 95% CI: 1.05-1.10; OR: 1.33, 95% CI: 1.21-1.58; OR: 0.82, 95% CI: 0.67- 0.99,
respectively).

